Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.45 |
| ▸ | HPGD | P15428 | 7/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | XBP1 | P17861 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375249 | 0.88 | HTT (0.49) | ALDH1A1NPSR1HTTRXFP1KDM4E | |
| SCHEMBL4375542 | 0.87 | IMPDH2 (0.47) | ALDH1A1LMNANPC1RAB9AL3MBTL1 | |
| SCHEMBL8289772 | 0.84 | GRIA2 (0.46) | ALDH1A1NPSR1HTTRXFP1KDM4E | |
| SCHEMBL4373435 | 0.83 | ALDH1A1 (0.41) | ALDH1A1NPSR1HTTRXFP1KDM4E | |
| SCHEMBL11037745 | 0.81 | PIM1 (0.44) | ALDH1A1NPSR1HTTKDM4EHPGD | |
| SCHEMBL26113942 | 0.80 | ALDH1A1 (0.50) | ALDH1A1NPSR1HTTRXFP1KDM4E | |
| SCHEMBL31189689 | 0.80 | ALDH1A1 (0.50) | ALDH1A1NPSR1HTTRXFP1KDM4E | |
| SCHEMBL1126789 | 0.80 | ALDH1A1 (0.52) | ALDH1A1NPSR1HTTRXFP1KDM4E | |
| SCHEMBL4372506 | 0.79 | ALDH1A1 (0.38) | ALDH1A1NPSR1HTTRXFP1KDM4E | |
| SCHEMBL4374929 | 0.77 | MAPT (0.39) | ALDH1A1KDM4EHPGDLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| EP-1670757-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | ALDH1A1 2211/4885NPSR1 143/4885HTT 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.